Diagnostics of hemostasiological indicators of blood in patients with cervical cancer: standards, innovative models of the future (Ukraine)

Abstract

This article focused on “Diagnostics of hemostasiological indicators of blood in patients with cervical cancer: standards, innovative models of the future (Ukraine)”. Aims: The aims of this study are to investigate the current standards, the innovative models, prognostic and predictive value of hemostasiological indicators of blood in patients with cervical cancer and identifications of potential gaps and opportunities in the current standards and innovative models for hemostasiological assessment. Methodology: A descriptive cross-sectional study design was evaluated. Secondary data were collected. Descriptive statistics were obtained and utilised. Results: The result showed that in 2020, Ukraine had 20.3 new cervical cancer cases per 100,000 women, regardless of age. Age-standardised cervical cancer incidence was 14.3 per 100,000 women. In 2020, Ukraine's lifetime cervical cancer risk was 1.4%. It illustrates cervical cancer risk. Prothrombin Time is 11–14 seconds, Activated Partial Thromboplastin Time is 25–35 seconds, fibrinogen is 200–400 mg/dL, and platelet counts are 150,000–450,000/L. Thromboelastography is a viscoelastic test that dynamically assesses blood clot formation, strength, and lysis. This test helps doctors assess cervical cancer patients' haemostatic profile and thrombotic risk and establish thromboprophylaxis regimens. In advanced cervical cancer patients, prothrombin time, APTT, fibrinogen, D-dimer, and platelet count predict thrombotic events and poor prognosis. These signs extend VTE risk. Potential gaps or opportunities include a lack of established practices, few complicated hemostasiological tests, little research, lack of knowledge and teaching, and difficulties with monitoring and follow-up, especially in resource-poor areas. Standardising techniques, expanding access to cutting-edge hemostasiological tests, and remote monitoring, and running education and awareness campaigns are future potentials for research and development. Scientific Novelty: cutting-edge hemostasiological tests in cervical cancer. Conclusion: In conclusion, resolving global cervical cancer mortality disparities needs healthcare, cancer prevention, screening, awareness, socioeconomic variables, and creative hemostasiological evaluation models. Better care, thromboprophylaxis, and collaboration can improve cervical cancer outcomes worldwide.